Headquartered in 42 Hayarkon Street, Yavne Fiscal year ends December NASDAQ: MDWD mediwound.com
MediWound Ltd. is a biotechnology company developing enzymatic, non-surgical therapies for tissue repair. Its FDA-approved biologic, NexoBrid, is indicated for the enzymatic removal of eschar in thermal burns. NexoBrid is marketed in the United States (through partner Vericel), the European Union, Japan and other international markets, and is procured by the U.S. Biomedical Advanced Research and Development Authority (BARDA). MediWound earns revenue from product sales, development services (including U.S. government-funded programs) and license agreements and royalties. Its late-stage pipeline candidate, EscharEx, is an investigational therapy for debridement of chronic wounds and is being evaluated in the global Phase III VALUE trial in venous leg ulcers. The company is also developing a room-temperature-stable NexoBrid formulation for battlefield burn care, funded by the U.S. Department of War. It is expanding its NexoBrid manufacturing capacity and seeking U.S. government funding for a planned U.S.-based manufacturing facility. Updated
Revenue missed expectations by 47% because U.S. government development services work stalled, and management says it has no visibility on when funding talks for the planned U.S. plant turn into recognized revenue. The November offering is meant to fund the company through the EscharEx Phase III data readout.
MediWound Ltd. is a biotechnology company developing enzymatic, non-surgical therapies for tissue repair. Its FDA-approved biologic, NexoBrid, is indicated for the enzymatic removal of eschar in thermal burns.
The Wall Street consensus 12-month price target for MDWD is $30.67.